本次举牌后，太保寿险直接持有东阳光药H股股票6,058,588股，占其H股股本比例为5.38%；太保产险 直接持有东阳光药H股股票1,487,837股，占其H股股本比例为1.32%。太保寿险和太保产险均表示，将 本次投资纳入权益投资管理。受托管理人太保资产将密切关注企业的经营状况及市场后续反应，不排除 在后期继续追加投资的可能。 智通财经APP获悉，东阳光药(06887)午后涨近5%，截至发稿，涨4.6%，报56.9港元，成交额8648.81万 港元。 消息面上，8月13日，太保寿险和太保产险双双发布公告称，8月7日，东阳光药通过新发行H股作为换 股对价，通过吸收合并方式私有化其香港上市子公司宜昌东阳光长江药业股份有限公司，将两家公司原 持有的宜昌东阳光长江药业股份有限公司股票按照一定比例进行换股，被动触发本次举牌。 ...

智通财经APP获悉，根据2025年8月12日披露数据，龙蟠科技(02465)、德林控股(01709)、匯通达网络 (09878)港股通持股占比增加值最大，分别增加3.25%、2.51%、2.39%；凯莱英(06821)、东阳光药 (06887)、阜博集团(03738)港股通持股占比减少值最大，分别减少-3.38%、-1.55%、-1.26%。 在最近有统计数据的5个交易日内，长飞光纤光缆(06869)、德林控股(01709)、美中嘉和(02453)港股通持 股占比增加值最大，分别增加7.59%、7.29%、3.93%；恆生中国企业(02828)、宜搜科技(02550)、盈富 基金(02800)港股通持股占比减少值最大，分别减少-16.55%、-8.76%、-6.77%。 具体数据如下(交易所数据根据T+2日结算)： 1、港股通最新日占比增持榜(前20名) 公司名称 占比值变动 最新持股比例 龙蟠科技(02465) +3.25% 46.51% 德林控股(01709) +2.51% 25.62% 匯通达网络(09878) +2.39% 29.81% 国富氢能(02582) +1.96% 2.79% 恆生中国企业( ...

Summary of Key Points Core Viewpoint - A total of 142 stocks reached their 52-week highs as of August 12, with notable performers including Yingmei Holdings (02028), Elite Group (01775), and Fuying Global Group (01620) achieving high rates of 164.89%, 84.78%, and 40.63% respectively [1]. Stock Performance - **Top Performers**: - Yingmei Holdings (02028) closed at 0.223 with a peak of 0.249, marking a 164.89% increase [1]. - Elite Group (01775) closed at 0.350 with a peak of 0.425, reflecting an 84.78% increase [1]. - Fuying Global Group (01620) closed at 0.180, reaching its peak at 0.180, showing a 40.63% increase [1]. - **Other Notable Stocks**: - Aoya Group (02425) increased by 34.36% [1]. - Fuyiy International Holdings (01470) saw a rise of 28.30% [1]. - Huajian Medical (01931) experienced a 27.58% increase [1]. 52-Week High Rankings - The ranking of stocks that reached their 52-week highs includes: - Yingmei Holdings (02028) at 164.89% [1]. - Elite Group (01775) at 84.78% [1]. - Fuying Global Group (01620) at 40.63% [1]. 52-Week Low Rankings - The report also highlights stocks that reached their 52-week lows, with notable declines including: - Jiadeng International Group (08153) at -15.25% [4]. - Kun Group (00924) at -12.86% [4]. - Zhongjia Guoxin (00899) at -10.00% [4].

Group 1: Company Filings - Three companies submitted applications to the Hong Kong Stock Exchange (HKEX) from August 4 to August 10, with one company passing the hearing [1] - Fujian Haixi New Drug Creation Co., Ltd. (Haixi New Drug) is a pharmaceutical company with a diverse product portfolio and pipeline, having received approvals for 14 generic drugs and four innovative drugs in development. Revenue for 2022 to 2025 is projected to be approximately RMB 2.12 billion, RMB 3.17 billion, RMB 4.67 billion, and RMB 2.49 billion respectively [2] - Shenzhen Haiqing Zhiyuan Technology Co., Ltd. (Haiqing Zhiyuan) specializes in multispectral AI technology, holding a 3.5% market share in the Chinese multispectral AI industry, ranking first. Revenue for 2022 to 2025 is projected to be approximately RMB 2.25 billion, RMB 1.17 billion, RMB 5.23 billion, and RMB 824.2 million respectively [3] - Ningbo Joyson Electronic Corp. (Joyson Electronics) is a provider of smart automotive technology solutions, ranking as the second-largest supplier of passive safety products in China and globally. Revenue for 2022 to 2025 is projected to be approximately RMB 49.793 billion, RMB 55.728 billion, RMB 55.864 billion, and RMB 19.709 billion respectively [4] Group 2: Company Hearings and Listings - Shuangdeng Group Co., Ltd. (Shuangdeng) passed the listing hearing on August 10, focusing on energy storage solutions for the big data and communications sectors. Revenue for 2022 to 2025 is projected to be approximately RMB 4.072 billion, RMB 4.260 billion, RMB 4.499 billion, and RMB 1.867 billion respectively [5][6] - Two companies are in the process of going public: Yinnuo Pharmaceutical-B (02591.HK) plans to offer 36.56 million H-shares at HKD 18.68 per share, while Zhonghui Biotechnology-B (02627.HK) plans to offer 33.44 million H-shares at HKD 12.90 per share, with the latter seeing a subscription rate of 4,007.64 times [7] - Dongyang Sunshine Pharmaceutical (HK:06887) was listed on August 7, 2025, closing at HKD 59.90, reflecting a 4.17% increase [8] Group 3: Market Trends and Regulations - The Hong Kong IPO market has raised nearly HKD 130 billion this year, with new regulations effective from August 4 aimed at optimizing pricing and allocation mechanisms for IPOs [9] - As of July 25, 2025, 52 companies have listed on the Hong Kong Stock Exchange, nearing the total of 75 for the previous two years combined. A notable trend is the increasing number of A-share companies seeking to list in Hong Kong [10] - The Hong Kong Stock Exchange aims to enhance the robustness of new stock pricing and allocation mechanisms to meet the needs of various local and international investors [11]

Group 1 - Dongyangguang Pharmaceutical successfully listed on the Hong Kong Stock Exchange, marking the first case of H-share absorption merger and privatization introduction listing on the exchange [2] - The company's stock price fell on its debut, closing down 0.56% on August 7 and continuing to decline by 6.09% on August 8, attributed to profit-taking by existing shareholders and market adjustments in the innovative drug sector [2] - The company has 150 approved drugs across various regions, with 48 sold in China and 23 in overseas markets, focusing on infection, chronic diseases, and oncology [3] Group 2 - The core product, Oseltamivir phosphate, once held a 90% market share in China but is now facing significant growth challenges, with its market share projected to drop from 64.8% in 2023 to 54.8% in 2024 [3] - Revenue from anti-infection drugs plummeted to 2.798 billion RMB in 2024, a 69.6% share of total revenue, down from 63.86 billion RMB in 2023 to 40.19 billion RMB in 2024 [4][3] - The company reported a 40.7% year-on-year revenue decline in Q1 2025, primarily due to a high revenue base from the flu season in late 2023 [4] Group 3 - Profitability has been unstable, with net profits of -1.416 billion RMB in 2022, 1.014 billion RMB in 2023, and 24.803 million RMB in 2024 [5] - Over 70 pharmaceutical companies in China produce Oseltamivir phosphate, intensifying market competition [5] - The company is diversifying its portfolio, particularly in chronic disease treatments, which have begun to offset the poor performance of flu medications [6] Group 4 - Chronic disease treatment drugs contributed 26.6% of total revenue in 2024, indicating a significant growth area for the company [7] - The company has 49 Class 1 innovative drugs in its pipeline, with one already submitted for NDA and ten in clinical trials, which may support future growth [8] - The success of the chronic disease segment and the innovative pipeline will be crucial for the company's ability to overcome current challenges [8]

Core Viewpoint - Dongyangguang Pharmaceutical (06887.HK) has officially listed on the Hong Kong Stock Exchange, marking the first case of H-share absorption and merger privatization combined with a listing in the Hong Kong market, creating a comprehensive innovative drug platform that integrates R&D, production, and sales [1][2] Group 1: Company Overview - The listing of Dongyangguang Pharmaceutical is a consolidation of the pharmaceutical resources under Dongyangguang Group, absorbing Dongyangguang Changjiang Pharmaceutical (01558.HK), which was previously a platform for the biopharmaceutical sector [2] - Dongyangguang Pharmaceutical is one of the largest producers of Oseltamivir globally and holds a leading position domestically [4] Group 2: R&D and Product Pipeline - The company has a robust R&D platform covering the entire lifecycle of chemical and biological drugs, with advanced technologies such as small nucleic acids, ADC, PROTAC, and specific antibodies [5] - As of the latest report, Dongyangguang Pharmaceutical has over 100 drugs in the pipeline, including 49 Class 1 innovative drugs in China, with several in Phase II or III clinical trials [7] - The company has successfully launched three Class 1 innovative drugs in the infection field, forming a unique combination of anti-hepatitis C drugs with independent intellectual property rights [8] Group 3: Market Potential and Growth Strategy - The diabetes drug market in China is projected to reach RMB 676 billion in 2023, with expectations to grow to RMB 903 billion and RMB 1,223 billion by 2026 and 2030, respectively [9] - Dongyangguang Pharmaceutical is expanding into chronic disease areas, including metabolic, cardiovascular, and chronic respiratory diseases, with promising candidates like HEC585 for idiopathic pulmonary fibrosis [9] - The company is accelerating its business development through licensing agreements, collaborations, and acquisitions, exemplified by a nearly $1 billion overseas licensing agreement with UK-based Apollo for the HEC88473 project [9] Group 4: Strategic Positioning - Following the absorption of Dongyangguang Changjiang Pharmaceutical, the company has established an integrated R&D, production, and sales model, driven by innovation and internationalization, positioning itself as a benchmark for innovative drugs with global influence [10]

东阳光药(06887.HK)吸收合并东阳光长江药业，今日正式在港交所主板上市。合并后，依托东阳光药深 厚的研发积淀和全方位的国际化布局，形成研产销一体化闭环，叠加"创新+国际化"双引擎驱动，持续 打造高潜力重磅产品，加速商业化进程和推动出海交易，成为深耕中国市场并具备全球影响力的创新药 标杆企业。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本聯合公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本聯合公 告 全 部 或 任 何 部 份 內 容 而 產 生 或 因 倚 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任。 （ 一間於中華人民共和國註冊成立的有限公司 ） 本聯合公告僅供參考，並不構成收購、購買或認購本公司證券之邀請或要約，亦 非在任何司法管轄區招攬任何投票或批准。 本聯合公告不會在構成違反任何司法管轄區相關法律的情況下於或向有關司法管 轄區發佈、刊發或派發。 宜昌東陽光長江藥業股份有限公司 YICHANG HEC CHANGJIANG PHARMACEUTICAL CO ., LTD . （ 在中華人民共和國註冊成立之股份有限公司 ） （股份代號：6887） （股份代號：1558） 聯合公告 以吸收合併宜昌東陽光長江藥業股份有限公司之方式 由廣東東陽光藥業股份有限公司 對宜昌東陽光長江藥業股份有限公司作出有條件私有化的最新進展 (1) 達成實施條件及實施合併 廣東東陽光藥業股份有限公司 SUNSHINE LAKE PHARMA CO ...

SUNSHINE LAKE PHARMA CO., LTD. 廣東東陽光藥業股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 張英俊博士 李文佳博士 非執行董事 張寓帥先生 唐新發先生 朱英偉先生 曾學波先生 東曉維女士 王蕾女士 獨立非執行董事 （股份代號：6887） 董事名單及其角色及職能 廣東東陽光藥業股份有限公司董事（「董事」）會（「董事會」）成員載列如下： 執行董事 1 董事會下設四個委員會。下表提供該等委員會的成員資料。 | 董事 | 董事委員會 | | | | | --- | --- | --- | --- | --- | | | 薪酬與 | | | | | | 審計委員會 考核委員會 | | 提名委員會 | 戰略委員會 | | 張英俊博士 | – | M | M | C | | 唐新發先生 | M | – | – | – | | 曾學波先生 | – | – | – | M | | 李新天博士 | M | M | M | – | | 尹航博士 | – | – | C | M | | 林愛梅博士 | C | C | – | – | 2 李新天博士 馬大為博士 尹航博士 林愛梅博士 葉濤博士 ...

廣東東陽光藥業股份有限公司 董事會薪酬與考核委員會工作細則 第一章 總則 第一條 為進一步建立健全廣東東陽光藥業股份有限公司（以下簡稱「公司」） 董事及高級管理人員的考核和薪酬管理制度，完善公司治理結構，根據《中華人 民共和國公司法》《中華人民共和國證券法》《上市公司治理準則》《香港聯合交 易所有限公司證券上市規則》（以下簡稱「《上市規則》」）等境內外上市公司監管 法規及公司於H股上市後生效的《廣東東陽光藥業股份有限公司章程》（以下簡稱 「《公司章程》」）的相關規定及其他法律、法規、規範性文件的規定，公司特設立 公司董事會（以下簡稱「董事會」）薪酬與考核委員會（以下簡稱「薪酬與考核委員 會」），並制定本工作細則。 第二條 薪酬與考核委員會是董事會按照《公司章程》設立的專門工作機構， 在其職責許可權範圍內擬定董事和高級管理人員的薪酬方案、績效考核制度以及 激勵方案，向董事會提出建議。薪酬與考核委員會向董事會報告工作，並對董事 會負責。 本規則所稱高級管理人員是指公司的總經理、副總經理、財務負責人、董事 會秘書和董事會認定的其他高級管理人員。 第二章 人員組成 第三條 薪酬與考核委員會成員至少由三名董事組成，過半 ...